IceCure enrols initial patients for ProSense cryoablation trial in US

IceCure Medical has enrolled its first two patients in the US for the ChoICE study, evaluating its ProSense cryoablation system for low-risk breast cancer treatment. The trial aims to recruit 400 patients across 30 centers. ProSense is FDA-cleared for treating small, low-risk breast tumors in patients aged 70+ who are ineligible for surgery. The company aims to gather real-world evidence and expand clinical adoption.

Original reporting
Published Oct 21, 2026, 10:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
IceCure enrols initial patients for ProSense cryoablation trial in US — source image
Decision brief

The 30-second read

Low
01

Why it matters

The enrollment of the first patients is a primary disclosure that could lift the stock as investors view it as a de‑risking milestone.

02

Market read

First‑patient enrollment in a cleared breast‑cancer device trial is a fresh catalyst for IceCure Medical (ICU).

03

What to watch

Reimbursement policies and competition from alternative ablation technologies could limit adoption.

Relevance 6/10Novelty 7/10Timing: today

Background

IceCure Medical is expanding its ProSense cryoablation system into a post‑marketing US trial after FDA clearance.

Market effects

May increase interest in minimally invasive breast‑cancer devices and related oncology tech.

Supports US biotech activity and trial site expansion.

Limited to niche oncology device market.

Counterpoint

Early enrollment does not guarantee successful outcomes; later trial phases could face setbacks.

Key entities

  • IceCure Medical

    Developer of the ProSense cryoablation system.

  • West Cancer Center & Research Institute

    First US site enrolling a patient.

  • Adventist Health Glendale

    Second US site enrolling a patient.

Related articles

$ICCMMed

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.